31
Participants
Start Date
March 6, 2015
Primary Completion Date
September 1, 2019
Study Completion Date
November 2, 2019
Pembrolizumab and high dose interferon alfa-2b (HDI)
Pembrolizumab and HDI will be given concurrently during the induction phase of the study for up to 6 weeks from treatment initiation. This is followed by surgery. After recovery from surgery, pembrolizumab and HDI will be reinitiated as maintenance therapy during the maintenance phase of the study.
Roswell Park Cancer Institute, Buffalo
Hillman Cancer Center, Pittsburgh
Merck Sharp & Dohme LLC
INDUSTRY
Yana Najjar
OTHER